Biologics and postbiologics: novel immunotherapeutics for the induction and maintenance of remission

Willem van Eden, Jeffrey Lisse, Berent Prakken, Salvatore Albani

Research output: Contribution to journalReview article

5 Scopus citations


Rapid growth in the development of new tools and advances in molecular immunology has led to a class of drugs called biologics. While effective, these therapies are costly, typically require continuous administration and often have serious side effects. This review focuses on current therapies and the need for a new class of therapies. A novel class of drugs able to induce and maintain tolerance will be paralleled with the notion that combination therapy appropriately tailored to patient subpopulations may hold the promise of less costly and more effective therapy.

Original languageEnglish (US)
Pages (from-to)71-77
Number of pages7
JournalDrug Discovery Today
Issue number1-2
StatePublished - Jan 1 2010


ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this